Creo Medical Group plc (AIM: CREO), a medical device company focused on the emerging field of surgical endoscopy, announces the successful first treatment of patients in the US using its Speedboat device powered by the Company’s CROMA electrosurgery advanced energy platform.
As part of the Company’s strategy to establish a training-centric commercialisation programme in the US two gastrointestinal surgeons from the same hospital were trained in the use of the Speedboat device over the weekend and each performed successful operations on patients this week. The two procedures were performed in both the upper and lower gastrointestinal (GI) tract respectively.
The Company expects to increase the number of trained clinicians in the US as the roll-out of the Creo Clinical Education Programme continues and looks forward to updating shareholders on further positive progress in this key market.
Speedboat is the first device developed for use with Creo’s CROMA generator, an electrosurgical platform that combines bipolar radiofrequency for precise, localised cutting and microwave for controlled coagulation. The Speedboat harnesses the cut and coagulation of the generator to enable the removal of cancerous and pre-cancerous GI growths.
Patients have now been successfully treated using the Speedboat device powered by Creo’s CROMA platform in the UK, South Africa, Mainland Europe and the US.
Craig Gulliford, Creo’s Chief Executive Officer, commented:
The US is clearly a key market for the Company and the successful completion of the first procedures in the United States is another important milestone for us. Over the next few weeks and months we expect to see our Clinical Education Programme expand in the US and we will continue to update shareholders as our training-led commercialisation strategy advances.
For press enquiries please contact media@creomedical.com. For all other enquiries please visit our Contact page.